Bloomberg Law• Apr 30, 2026• 28:50Interview

Supreme Court Guts Voting Rights Act & Bayer Litigation | Bloomberg Law

From Bloomberg Law

Rick Hassan•Professor, UCLA Law School

Executive Summary

Supreme Court has effectively nullified Section 2 of the Voting Rights Act in a ruling on a Louisiana congressional district, establishing a new, nearly impossible standard for minority voters to challenge discriminatory maps.
The decision is described as an 'earthquake' in election law, expected to significantly reduce minority representation in Congress and state legislatures, while providing a defense for partisan gerrymandering.
Bayer is before the Supreme Court arguing that federal EPA approval of its Roundup product label should preempt state-level lawsuits alleging it failed to warn consumers about cancer risks, a case with over $17 billion in potential liability.
A new book, 'The Pain Brokers,' highlights a predatory scheme where private healthcare data was sold to mass tort lawyers to solicit plaintiffs, exposing significant vulnerabilities in patient data privacy.

12 quotes

Concerns Raised

The Supreme Court's ruling will lead to a significant decrease in minority political representation.
The new legal standard for voting rights claims is nearly impossible for plaintiffs to meet, effectively nullifying key protections.
Partisan gerrymandering is now a permissible defense against claims of minority vote dilution.
Private healthcare data is being actively sold and weaponized by players in the mass tort legal system.
Bayer faces massive, potentially existential, financial liability from Roundup litigation.

Opportunities Identified

Congress has the authority to pass new legislation to strengthen the Voting Rights Act, as the Supreme Court's decision was based on statutory interpretation.
A Supreme Court ruling in Bayer's favor could provide legal certainty and limit liability for companies in federally regulated industries.

Key Themes

The Evisceration of the Voting Rights Act

The Supreme Court's conservative majority issued a landmark decision that fundamentally alters the application of the Voting Rights Act. The ruling creates a new 'race-blind' standard for redistricting challenges that experts believe is virtually impossible for minority plaintiffs to meet, effectively rendering Section 2 of the act a 'dead letter'.

This ruling significantly impacts the political landscape by potentially rolling back decades of progress in minority representation, altering the composition of Congress and state legislatures, and sanctioning partisan gerrymandering as a defense against vote dilution claims.

Federal Preemption vs. State Consumer Protection

The Bayer Roundup case before the Supreme Court centers on whether federal law and EPA regulations preempt state-level 'failure-to-warn' lawsuits. Bayer argues it cannot be sued under state law for not including a cancer warning that the EPA did not require, while plaintiffs argue companies must still respond to emerging scientific evidence of harm.

The outcome will have profound implications for all federally regulated industries, including pharmaceuticals, medical devices, and food, by defining the balance of power between federal regulatory approval and a state's ability to protect its citizens through tort law.

The Politicization of the Judiciary

The 6-3 ideological split in the Voting Rights Act decision is presented as evidence of the Supreme Court's increasing alignment with partisan political outcomes. The guest notes that regardless of intent, the conservative majority's jurisprudence consistently benefits the Republican party's political agenda, fueling calls for court reform.

This perception erodes public trust in the judiciary as an impartial institution and frames legal battles as extensions of political warfare, potentially leading to greater political pressure on the courts and challenges to their legitimacy.

Corporate Liability in Mass Tort Litigation

Bayer's legal battle over Roundup exemplifies the immense scale and financial risk of modern mass tort litigation. The company faces over 100,000 lawsuits, has already spent over $10 billion, and faces billions more in liability, all stemming from scientific debate over the safety of its product's key ingredient, glyphosate.

This highlights the catastrophic financial and reputational risk companies face from product liability, demonstrating that regulatory compliance alone may not be a sufficient shield against litigation when public health concerns arise.

Healthcare Data Privacy and Exploitation

The discussion of 'The Pain Brokers' reveals a dark side of the legal industry, where private health information is illicitly acquired and used to solicit clients for mass tort lawsuits. A subsidiary of EPIC Systems admitted to selling such data, which was then used to pressure vulnerable patients into unnecessary and harmful medical procedures to inflate settlement values.

This exposes a critical vulnerability in the healthcare data ecosystem and a predatory business model within the mass tort system, posing significant risks to both patient privacy and physical well-being.

Get started free

Topics

Supreme Court Voting Rights Act Section 2 Redistricting Gerrymandering Election Law Minority Representation Constitutional Law Bayer Roundup Glyphosate Mass Tort Litigation Product Liability Federal Preemption EPA Healthcare Data Privacy

Processed Apr 30, 2026 yt-dlp + mlx-whisper + Gemini

You're reading a preview

Get started free →